The estimated Net Worth of Sharathchandra S Hegde is at least $2.37 Million dollars as of 4 March 2019. Sharathchandra Hegde owns over 9,033 units of Theravance Biopharma Inc stock worth over $2,141,996 and over the last 9 years Sharathchandra sold TBPH stock worth over $223,205.
Sharathchandra has made over 1 trades of the Theravance Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Sharathchandra sold 9,033 units of TBPH stock worth $223,205 on 4 March 2019.
The largest trade Sharathchandra's ever made was selling 9,033 units of Theravance Biopharma Inc stock on 4 March 2019 worth over $223,205. On average, Sharathchandra trades about 411 units every 0 days since 2016. As of 4 March 2019 Sharathchandra still owns at least 264,444 units of Theravance Biopharma Inc stock.
You can see the complete history of Sharathchandra Hegde stock trades at the bottom of the page.
Sharathchandra's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: